{"id":33292,"date":"2020-03-23T20:35:19","date_gmt":"2020-03-23T20:35:19","guid":{"rendered":"https:\/\/beyondtype2.org\/?post_type=resources&#038;p=33292"},"modified":"2025-07-01T22:52:40","modified_gmt":"2025-07-01T22:52:40","slug":"trial-dfmo","status":"publish","type":"resources","link":"https:\/\/beyondtype1.org\/es\/trial-dfmo\/","title":{"rendered":"DFMO en Ni\u00f1os con Diabetes Tipo 1"},"content":{"rendered":"<p><em>Patrocinado por la <strong>Universidad de Indiana<\/strong>&nbsp;<\/em><\/p>\n<hr>\n<h3>&Aacute;reas de Enfoque: <a href=\"https:\/\/beyondtype1.org\/beta-cell-therapies\/\" target=\"_blank\" rel=\"noopener noreferrer\">Terapias de C&eacute;lulas Beta&nbsp;<\/a><\/h3>\n<h3><b>&iquest;De qu&eacute; se trata este estudio?&nbsp;&nbsp;<\/b><\/h3>\n<div class=\"jhH5U\">\n<div id=\"tw-ob\" class=\"tw-src-ltr\">\n<div class=\"oSioSc\">\n<div id=\"tw-target\" class=\"\">\n<div id=\"kAz1tf\" class=\"g9WsWb\">\n<div id=\"tw-target-text-container\" class=\"tw-ta-container hide-focus-ring tw-nfl\" tabindex=\"0\">\n<p id=\"tw-target-text\" class=\"tw-data-text tw-text-large tw-ta\" dir=\"ltr\" data-placeholder=\"Traducci&oacute;n\"><span lang=\"es\">En este estudio de fase 1, la alfa difluorometillornitina (DFMO), un medicamento que se usa con frecuencia para tratar enfermedad de sue&ntilde;o, se administra a participantes entre 12 y 40 a&ntilde;os que han sido diagnosticados con diabetes Tipo 1 en los &uacute;ltimos 2-8 meses. Se ha demostrado que DFMO preserva la producci&oacute;n de c&eacute;lulas beta y retrasa la aparici&oacute;n de diabetes en ratones.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h3><b>&iquest;Por Qu&eacute; Nos Interesa?<\/b><\/h3>\n<div class=\"jhH5U\">\n<div id=\"tw-ob\" class=\"tw-src-ltr\">\n<div class=\"oSioSc\">\n<div id=\"tw-target\" class=\"\">\n<div id=\"kAz1tf\" class=\"g9WsWb\">\n<div id=\"tw-target-text-container\" class=\"tw-ta-container hide-focus-ring tw-nfl\" tabindex=\"0\">\n<p id=\"tw-target-text\" class=\"tw-data-text tw-text-large tw-ta\" dir=\"ltr\" data-placeholder=\"Traducci&oacute;n\"><span lang=\"es\">Este es un tipo de medicamento completamente nuevo para la preservaci&oacute;n de las c&eacute;lulas beta. Como estudio de fase 1, el resultado primario es determinar qu&eacute; nivel seguro de DFMO es de hasta 750 mg por d&iacute;a. Los resultados secundarios ser&aacute;n medir los biomarcadores del estr&eacute;s de las c&eacute;lulas beta, as&iacute; como las medidas de producci&oacute;n de insulina \/ glucemia. Si se demuestra que este medicamento es seguro a dosis m&aacute;s altas, ser&aacute; un enfoque emocionante y novedoso para desacelerar y prevenir el desarrollo de DT1.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h3><b>&iquest;Cu&aacute;ndo Podr&iacute;amos Ver Resultados?&nbsp;&nbsp;<\/b><\/h3>\n<div class=\"jhH5U\">\n<div id=\"tw-ob\" class=\"tw-src-ltr\">\n<div class=\"oSioSc\">\n<div id=\"tw-target\" class=\"\">\n<div id=\"kAz1tf\" class=\"g9WsWb\">\n<div id=\"tw-target-text-container\" class=\"tw-ta-container hide-focus-ring tw-nfl\" tabindex=\"0\">\n<p id=\"tw-target-text\" class=\"tw-data-text tw-text-large tw-ta\" dir=\"ltr\" data-placeholder=\"Traducci&oacute;n\"><span lang=\"es\">Se esperan resultados para este estudio a fines de 2020.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h3><b>Lecturas Adicionales<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Mantente atento a la cobertura a fondo de Beyond Type 1 sobre los resultados de este estudio. <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02384889\" target=\"_blank\" rel=\"noopener noreferrer\">Para obtener m&aacute;s informaci&oacute;n sobre esta prueba, haz clic aqu&iacute;.<\/a><\/span><\/p>\n<h3><b>Encuentra un Ensayo Cl&iacute;nico Cerca de Ti&nbsp;<\/b><\/h3>\n<p><script src=\"https:\/\/antidote.me\/unisearch\/js\/embed.js?utm_source=beyondtype1_org&amp;utm_medium=referral&amp;utm_campaign=unisearch&amp;width%20=640&amp;height=360&amp;color=6adfe6&amp;font=sans&amp;condition=Type%201%20Diabetes\" async=\"true\"><span data-mce-type=\"bookmark\" style=\"display: inline-block; width: 0px; overflow: hidden; line-height: 0;\" class=\"mce_SELRES_start\">&#65279; script><span data-mce-type=\"bookmark\" style=\"display: inline-block; width: 0px; overflow: hidden; line-height: 0;\" class=\"mce_SELRES_start\">\n<span data-mce-type=\"bookmark\" style=\"display: inline-block; width: 0px; overflow: hidden; line-height: 0;\" class=\"mce_SELRES_start\">&#65279;\n<\/script><\/p>\n\n","protected":false},"excerpt":{"rendered":"<p>Patrocinado por la Universidad de Indiana&nbsp; &Aacute;reas de Enfoque: Terapias de C&eacute;lulas Beta&nbsp; &iquest;De qu&eacute; se trata este estudio?&nbsp;&nbsp; En este estudio de fase 1, la alfa difluorometillornitina (DFMO), un medicamento que se usa con frecuencia para tratar enfermedad de sue&ntilde;o, se administra a participantes entre 12 y 40 a&ntilde;os que han sido diagnosticados con [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":33293,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-33292","resources","type-resources","status-publish","has-post-thumbnail","hentry","content-categories-educacion","topics-cuidado-de-la-salud","topics-defensa","topics-insulina-y-medicamentos","diabetes-types-tipo-1","tags-activetrial-es","tags-betacelltrial-es"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DFMO en Ni\u00f1os con Diabetes Tipo 1 | Beyond Type 1<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/beyondtype1.org\/es\/trial-dfmo\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DFMO en Ni\u00f1os con Diabetes Tipo 1 | Beyond Type 1\" \/>\n<meta property=\"og:description\" content=\"Patrocinado por la Universidad de Indiana&nbsp; &Aacute;reas de Enfoque: Terapias de C&eacute;lulas Beta&nbsp; &iquest;De qu&eacute; se trata este estudio?&nbsp;&nbsp; En este estudio de fase 1, la alfa difluorometillornitina (DFMO), un medicamento que se usa con frecuencia para tratar enfermedad de sue&ntilde;o, se administra a participantes entre 12 y 40 a&ntilde;os que han sido diagnosticados con [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/beyondtype1.org\/es\/trial-dfmo\/\" \/>\n<meta property=\"og:site_name\" content=\"Beyond Type 1\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/beyondtype1\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-01T22:52:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/12\/BT1-DFMO-CHILDREN-TYPE-1-DIABETES-HEADER-1200x429-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"429\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@BeyondType1\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/beyondtype1.org\/es\/trial-dfmo\/\",\"url\":\"https:\/\/beyondtype1.org\/es\/trial-dfmo\/\",\"name\":\"DFMO en Ni\u00f1os con Diabetes Tipo 1 | Beyond Type 1\",\"isPartOf\":{\"@id\":\"https:\/\/beyondtype1.org\/es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/beyondtype1.org\/es\/trial-dfmo\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/beyondtype1.org\/es\/trial-dfmo\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/12\/BT1-DFMO-CHILDREN-TYPE-1-DIABETES-HEADER-1200x429-1.png\",\"datePublished\":\"2020-03-23T20:35:19+00:00\",\"dateModified\":\"2025-07-01T22:52:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/beyondtype1.org\/es\/trial-dfmo\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/beyondtype1.org\/es\/trial-dfmo\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/beyondtype1.org\/es\/trial-dfmo\/#primaryimage\",\"url\":\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/12\/BT1-DFMO-CHILDREN-TYPE-1-DIABETES-HEADER-1200x429-1.png\",\"contentUrl\":\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/12\/BT1-DFMO-CHILDREN-TYPE-1-DIABETES-HEADER-1200x429-1.png\",\"width\":1200,\"height\":429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/beyondtype1.org\/es\/trial-dfmo\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/beyondtype1.org\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DFMO en Ni\u00f1os con Diabetes Tipo 1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/beyondtype1.org\/es\/#website\",\"url\":\"https:\/\/beyondtype1.org\/es\/\",\"name\":\"Beyond Type 1\",\"description\":\"Beyond Type 1 is the largest diabetes org online, funding advocacy, education and cure research.\",\"publisher\":{\"@id\":\"https:\/\/beyondtype1.org\/es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/beyondtype1.org\/es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/beyondtype1.org\/es\/#organization\",\"name\":\"Beyond Type 1\",\"url\":\"https:\/\/beyondtype1.org\/es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/beyondtype1.org\/es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2025\/08\/header-logo.svg\",\"contentUrl\":\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2025\/08\/header-logo.svg\",\"width\":56,\"height\":56,\"caption\":\"Beyond Type 1\"},\"image\":{\"@id\":\"https:\/\/beyondtype1.org\/es\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/beyondtype1\",\"https:\/\/x.com\/BeyondType1\",\"http:\/\/instagram.com\/BeyondType1\/\",\"https:\/\/www.youtube.com\/c\/BeyondType1\",\"https:\/\/www.tiktok.com\/@beyondtype1\",\"https:\/\/www.linkedin.com\/company\/beyond-type1\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DFMO en Ni\u00f1os con Diabetes Tipo 1 | Beyond Type 1","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/beyondtype1.org\/es\/trial-dfmo\/","og_locale":"es_ES","og_type":"article","og_title":"DFMO en Ni\u00f1os con Diabetes Tipo 1 | Beyond Type 1","og_description":"Patrocinado por la Universidad de Indiana&nbsp; &Aacute;reas de Enfoque: Terapias de C&eacute;lulas Beta&nbsp; &iquest;De qu&eacute; se trata este estudio?&nbsp;&nbsp; En este estudio de fase 1, la alfa difluorometillornitina (DFMO), un medicamento que se usa con frecuencia para tratar enfermedad de sue&ntilde;o, se administra a participantes entre 12 y 40 a&ntilde;os que han sido diagnosticados con [&hellip;]","og_url":"https:\/\/beyondtype1.org\/es\/trial-dfmo\/","og_site_name":"Beyond Type 1","article_publisher":"https:\/\/www.facebook.com\/beyondtype1","article_modified_time":"2025-07-01T22:52:40+00:00","og_image":[{"width":1200,"height":429,"url":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/12\/BT1-DFMO-CHILDREN-TYPE-1-DIABETES-HEADER-1200x429-1.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@BeyondType1","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/beyondtype1.org\/es\/trial-dfmo\/","url":"https:\/\/beyondtype1.org\/es\/trial-dfmo\/","name":"DFMO en Ni\u00f1os con Diabetes Tipo 1 | Beyond Type 1","isPartOf":{"@id":"https:\/\/beyondtype1.org\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/beyondtype1.org\/es\/trial-dfmo\/#primaryimage"},"image":{"@id":"https:\/\/beyondtype1.org\/es\/trial-dfmo\/#primaryimage"},"thumbnailUrl":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/12\/BT1-DFMO-CHILDREN-TYPE-1-DIABETES-HEADER-1200x429-1.png","datePublished":"2020-03-23T20:35:19+00:00","dateModified":"2025-07-01T22:52:40+00:00","breadcrumb":{"@id":"https:\/\/beyondtype1.org\/es\/trial-dfmo\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/beyondtype1.org\/es\/trial-dfmo\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/beyondtype1.org\/es\/trial-dfmo\/#primaryimage","url":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/12\/BT1-DFMO-CHILDREN-TYPE-1-DIABETES-HEADER-1200x429-1.png","contentUrl":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/12\/BT1-DFMO-CHILDREN-TYPE-1-DIABETES-HEADER-1200x429-1.png","width":1200,"height":429},{"@type":"BreadcrumbList","@id":"https:\/\/beyondtype1.org\/es\/trial-dfmo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/beyondtype1.org\/es\/"},{"@type":"ListItem","position":2,"name":"DFMO en Ni\u00f1os con Diabetes Tipo 1"}]},{"@type":"WebSite","@id":"https:\/\/beyondtype1.org\/es\/#website","url":"https:\/\/beyondtype1.org\/es\/","name":"Beyond Type 1","description":"Beyond Type 1 is the largest diabetes org online, funding advocacy, education and cure research.","publisher":{"@id":"https:\/\/beyondtype1.org\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/beyondtype1.org\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/beyondtype1.org\/es\/#organization","name":"Beyond Type 1","url":"https:\/\/beyondtype1.org\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/beyondtype1.org\/es\/#\/schema\/logo\/image\/","url":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2025\/08\/header-logo.svg","contentUrl":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2025\/08\/header-logo.svg","width":56,"height":56,"caption":"Beyond Type 1"},"image":{"@id":"https:\/\/beyondtype1.org\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/beyondtype1","https:\/\/x.com\/BeyondType1","http:\/\/instagram.com\/BeyondType1\/","https:\/\/www.youtube.com\/c\/BeyondType1","https:\/\/www.tiktok.com\/@beyondtype1","https:\/\/www.linkedin.com\/company\/beyond-type1\/"]}]}},"_links":{"self":[{"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/resources\/33292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/resources"}],"about":[{"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/types\/resources"}],"author":[{"embeddable":true,"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/comments?post=33292"}],"version-history":[{"count":0,"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/resources\/33292\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/media\/33293"}],"wp:attachment":[{"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/media?parent=33292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}